{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:06:49Z","timestamp":1784642809440,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaut.2025.103455","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:27:20Z","timestamp":1751376440000},"page":"103455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stratifying patients by TNFSF13B genotype revealed increased flare and renal flare risk, but a greater benefit from belimumab: a potential biomarker for personalized treatment in systemic lupus erythematosus"],"prefix":"10.1016","volume":"155","author":[{"given":"Marta Paola","family":"Pireddu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Congiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Chessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maristella","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Deidda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela Rita","family":"Naitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Angioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-8315","authenticated-orcid":false,"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103455_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101938","article-title":"Clinical patterns of disease: from early systemic lupus erythematosus to late-onset disease","volume":"37","author":"Piga","year":"2023","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103455_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/09612033221074580","article-title":"The association between lupus serology and disease outcomes: a systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus","volume":"31","author":"Kostopoulou","year":"2022","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.jaut.2025.103455_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103455_bib4","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103455_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0961203315604909","article-title":"Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab","volume":"25","author":"Roth","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2025.103455_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103455_bib7","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"BLISS-76 study group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103455_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103455_bib9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the cytokine BAFF and autoimmunity risk","volume":"376","author":"Steri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103455_bib10","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1038\/s41598-018-26573-4","article-title":"Association of a rare variant of the TNFSF13B gene with susceptibility to rheumatoid arthritis and systemic lupus erythematosus","volume":"8","author":"Gonz\u00e1lez-Serna","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2025.103455_bib11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12882-019-1623-4","article-title":"Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis","volume":"20","author":"Friebus-Kardash","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.jaut.2025.103455_bib12","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"Development and initial validation of an updated version of the British Isles lupus assessment Group's disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103455_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"Classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2025.103455_bib14","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2025.103455_bib15","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S2665-9913(22)00107-2","article-title":"Physician global assessment international standardisation COnsensus in systemic lupus erythematosus: the PISCOS study","volume":"4","author":"Piga","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaut.2025.103455_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the systemic lupus international collaborating clinics\/American college of rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103455_bib17","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Asia-Pacific lupus collaboration. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaut.2025.103455_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jaut.2025.103455_bib19","first-page":"453","article-title":"Lupus foundation of America, inc. International flare consensus initiative","volume":"20","author":"Ruperto","year":"2011","journal-title":"International consensus for a definition of disease flare in lupus. Lupus"},{"key":"10.1016\/j.jaut.2025.103455_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint european league against rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103455_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.autrev.2016.02.019","article-title":"Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review","volume":"15","author":"Floris","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103455_bib22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","article-title":"Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates","volume":"48","author":"Peduzzi","year":"1995","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jaut.2025.103455_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.31138\/mjr.28.1.4","article-title":"Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies","volume":"28","author":"Adamichou","year":"2017","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.jaut.2025.103455_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/annrheumdis-2012-202443","article-title":"Annual direct medical cost of active systemic lupus erythematosus in five European countries","volume":"73","author":"Doria","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103455_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical disease activity and flare in SLE: current concepts and novel biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2025.103455_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103455_bib27","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.37995","article-title":"Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103455_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.42389","article-title":"A flare risk index informed by select immune mediators in systemic lupus erythematosus","volume":"75","author":"Munroe","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103455_bib29","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/ar1855","article-title":"B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels","volume":"8","author":"Collins","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103455_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.1102321","article-title":"Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors","volume":"188","author":"Kreuzaler","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103455_bib31","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103455_bib32","doi-asserted-by":"crossref","first-page":"12040","DOI":"10.1093\/nar\/gky866","article-title":"Cooperative translational control of polymorphic BAFF by NF90 and miR-15a","volume":"46","author":"Laura","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.jaut.2025.103455_bib33","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103455_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102729","article-title":"Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort","volume":"124","author":"Gatto","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2025.103455_bib35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","article-title":"Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review","volume":"9","author":"Huang","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaut.2025.103455_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-020-02177-0","article-title":"The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis","volume":"22","author":"Wilkinson","year":"2020","journal-title":"Arthritis Res. Ther."},{"issue":"7571","key":"10.1016\/j.jaut.2025.103455_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:10:35Z","timestamp":1753222235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"alternative-id":["S0896841125001003"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103455","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stratifying patients by TNFSF13B genotype revealed increased flare and renal flare risk, but a greater benefit from belimumab: a potential biomarker for personalized treatment in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103455"}}